Bharat Biotech’s COVAXIN Enters Phase-3 Trials

The Covid-19 vaccine named ‘Covaxin’, being developed by Bharat Biotech has entered Phase-3 trials. This was informed by Krishna Ella, Chairman and Managing Director, Bharat Biotech on Monday. “We partnered with ICMR for COVID-19 vaccine as we speak it entered the phase 3 trials,” he said.

Speaking virtually at a programme organised by the Indian School of Business, Ella said the company is also working on another vaccine for COVID-19 which would be in the form of nasal drops and can be ready by next year. It is to be noted that ‘Covaxin’ is being developed by BharatBiotech, in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). 

Last month the vaccine maker said that it had successfully completed interim analysis of Phase I and II trials of the vaccine and is initiating Phase-III trials in 26,000 participants. The third trial may be completed by early 2021. The most important thing is that India has been working on an affordable biotech vaccine, so it is expected that the ‘Covaxin’ may be the cheapest vaccine in the world.